This message is posted on behalf of Dr. Rafael Nunez: Please reply directly: ---------------------------------------------------------------- >Dear Dr. Porwitt-MacDonald: >Thank you very much for let us know about your interesting case. >Before that, we will like to ask: 1. At which clinical level the >patient had mediastinal mass or skin nodules? At their clinical >initial presentation or during the relapse? 2. It was checked the >expression of >CD38 on the cell surface of the Blasts? 3. Which were the karyotypic >results in both situations? >The case that you present could be categorized (retrospectively) from the >beginning as a Bi-phenotipic leukemia, based in T-cell expression antigens >with >T-cell receptor rearrangements plus expression of CD33, CD13, CD34. >In fact, at the relapse the common antigens that are expressed are: >TdT, CD7. CD34, CD33, CD13. However, the T cell diagnosis looked >the appropiate at diagnosis time. >I hope so that this information can be useful: >1.- In: Schmidt CA et als: Leuk Lymph, 1999,20:45-49: they present >several cases of the expression of TCR delta rearrangements >associated to T-antigens in AML, without a critical significance for >the TdT expression. >2.- However in: Farahat N et al: (Catovsky's team): Leukemia: >1995;9:583-7. The present that is not as critical the expression of >TdT but their intensity determined by flow cytometry that allow a >clear cut difference between B,T or AML. >3.- Oez S et al, in: Ann Hematol: 1996: 72:307-16. Present a cell >line derived from a patient with AML wich express a clear T cell >phenotype with expression of CD34 and acquisition of CD33, but spite >of different phenotypic variability in culture, it was not possible >to separate a subclone because the cells regain the same phenotypic >appearance with the time. >4.- Another 2 examples of bi-phenotypic T/Myeloid leukemias: >a.- Launder TM et als: Am J Clin Path: 1996:106:185-91 and >b.- Carbonell F et als. (Catovsky's team): Leukemia: 1996:10:1283-7 >Finally. It looks like this patient will have to receive Bone Marrow >transplant for the actual AML. >Please, let us know any comment that you have regarding the patient >outcome. >Sincerely: >Cesar Nunez, MD. >University of Manchester >School of Biological Sciences >G.38 Stopford Building >Oxford Road >Manchester M13 9PT >England >Rafael Nunez MD. MSc. Assist. Prof. >Institute of Virology, University of Zürich >Switzerland >rafaeln@vetvir.unizh.ch >cnunez@fs1.scg.man.ac.uk > > \|/ > (o o) >________________________________oOo__(_)__oOo______________________________ ___ > ___/\_ | Rafael Nunez mailto:rafaeln@vetvir.unizh.ch > / o \/| | University Inst.for Virology http://www.unizh.ch/vetvir > / _| | Winterthurerstr. 266a Telephone: (+41) 1 6358709 > /_/\__/-\/ | 8057 Zurich SWITZERLAND Faximile : (+41) 1 6358911 >___________________________________________________________________________ ___ Posted for the above by: __________________________________________________________________ J.Paul Robinson, Ph.D., Professor of Immunopharmacology Director, Purdue University Cytometry Laboratories Purdue University Phone:(765)-4940757 FAX: (765)-4040517 EMAIL: robinson@flowcyt.cyto.purdue.edu WEB: http://www.cyto.purdue.edu
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:49:45 EST